2023
DOI: 10.1016/j.ejphar.2023.175533
|View full text |Cite
|
Sign up to set email alerts
|

Adriforant is a functional antagonist of histamine receptor 4 and attenuates itch and skin inflammation in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 50 publications
0
0
0
Order By: Relevance
“…Two enantiomeric complementary IREDs were identified for the synthesis of (3R,4R)-and (3S,4S)-1-benzyl-4-dimethylpiperidin-3-amine, with high separation yield (83% and 91%), excellent stereoselectivity (97% and >99% ee) and diastereoselectivity (>99:1 dr), respectively, providing a green method for the production of key intermediates of Tofacitinib. 62 In 2022, researchers at Novartis developed a biosynthesis strategy of ZPL389 (H4 receptor antagonist) 63 catalyzed by the IR88 variant. 64 This enzyme catalytic pathway takes a large volume of pyrrolidone as substrate, and directly undergoes reductive amination with methylamine to obtain the catalytic product with up to 98% ee, and after being resolved by L-tartaric acid, the ee value of the product can reach 99%.…”
Section: Ired-mediated Synthesis Of Representative Drugsmentioning
confidence: 99%
See 1 more Smart Citation
“…Two enantiomeric complementary IREDs were identified for the synthesis of (3R,4R)-and (3S,4S)-1-benzyl-4-dimethylpiperidin-3-amine, with high separation yield (83% and 91%), excellent stereoselectivity (97% and >99% ee) and diastereoselectivity (>99:1 dr), respectively, providing a green method for the production of key intermediates of Tofacitinib. 62 In 2022, researchers at Novartis developed a biosynthesis strategy of ZPL389 (H4 receptor antagonist) 63 catalyzed by the IR88 variant. 64 This enzyme catalytic pathway takes a large volume of pyrrolidone as substrate, and directly undergoes reductive amination with methylamine to obtain the catalytic product with up to 98% ee, and after being resolved by L-tartaric acid, the ee value of the product can reach 99%.…”
Section: Ired-mediated Synthesis Of Representative Drugsmentioning
confidence: 99%
“…In 2022, researchers at Novartis developed a biosynthesis strategy of ZPL389 (H4 receptor antagonist) catalyzed by the IR88 variant . This enzyme catalytic pathway takes a large volume of pyrrolidone as substrate, and directly undergoes reductive amination with methylamine to obtain the catalytic product with up to 98% ee, and after being resolved by l -tartaric acid, the ee value of the product can reach 99%.…”
Section: Ired-mediated Synthesis Of Representative Drugsmentioning
confidence: 99%
“…Previous studies have shown that H4R activation regulates the phosphorylation of ERK in mast cells 10,11 . Recently, H4R was also reported to be co‐labelled with NeuN, a neuron maker, in the mouse spinal cord and DRG and involved in the regulation of chronic pain, itch and skin inflammation 12,13 . Whether H4R and p‐ERK in the spinal cord are involved in dry skin itch has not been investigated.…”
Section: Introductionmentioning
confidence: 99%